3. Jun 2026 | B2B_Patient_Engagement
Cardiovascular guidelines are considered the gold standard of evidence-based medicine. The recommendations of the European Society of Cardiology and the European Atherosclerosis Society for lowering LDL cholesterol are clear, differentiated by risk profiles, and...
6. May 2026 | B2B, B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD
How can complex medical knowledge be communicated in a way that is not only understood, but also applied in everyday life? This question concerns pharmaceutical companies as well as medical affairs teams and providers of digital health solutions. According to the...
1. Apr 2026 | B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD
Randomized phase III trials are the gold standard of evidence-based drug development. They provide robust data on efficacy and safety and form the basis for regulatory decisions. However, with market approval, a new phase of evidence generation begins: the real-world...
4. Mar 2026 | B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD
What Insights Digital Real-World Data Provide and Where Their Limits Lie Digital therapy companions are increasingly being discussed in the pharmaceutical industry as a potential source of patient insights. At the same time, it often remains unclear what kind of...
4. Feb 2026 | B2B_Patient_Engagement
Rethinking Omnichannel Pharma Omnichannel strategies are firmly established in the pharmaceutical industry and primarily aim at consistent, personalized communication with physicians. Numerous professional publications describe omnichannel as a further development of...
16. Jan 2026 | B2B_Patient_Engagement
Many people feel uncertain or alone when it comes to managing their medication. This makes it all the more important to not only provide patients with medical care, but also to give them clear and effective information. Now more than ever, health literacy is a...
